In clinical trials, Retatrutide showed significant promise, with early results suggesting it could offer greater weight loss than existing options like Wegovy and Zepbound
Peptides are not magic pills
Over the past two decades, the United States Food and Drug Administration (FDA) has approved two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treating obesity, of which include liraglutide and semaglutide
Image credits: roshanramani007 Image credits: DontWearMyShirt By contrast, synthetic pathways bypass this damage-driven response entirely
There used to be Belviq, but in 2020, the FDA requested a recall after a review of the original clinical trial results revealed a higher incidence of cancer when compared to the placebo group
They are critically important synergists